Denali Therapeutics Financial Ratios Analysis

Valuation, profitability, leverage, and liquidity ratios

Scroll to see more
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Valuation Ratios
P/E Ratio141.20
P/S Ratio8.9734.82111.9329.92
P/B Ratio2.382.883.625.668.73
Price/Tangible Book2.382.883.625.668.73
Price/FCF24.32
Price/OCF24.14
Enterprise Value Ratios
EV/Revenue5.7625.2085.3527.21
EV/EBITDA128.18
EV/EBIT145.62
EV/FCF22.11
Profitability & Returns
Return on Equity (ROE)-0.37%-0.14%-0.33%-0.28%0.09%
Return on Assets (ROA)-0.25%-0.09%-0.15%-0.12%0.04%
Return on Invested Capital (ROIC)-2.01%
Return on Capital Employed (ROCE)-0.40%-0.18%-0.31%-0.29%0.04%
Leverage & Solvency Ratios
Debt/Equity0.040.050.060.070.06
Debt/EBITDA0.87
Debt/FCF0.17
Liquidity Ratios
Current Ratio8.4613.653.772.3720.86
Quick Ratio8.1613.313.702.2920.58
Efficiency Ratios
Asset Turnover0.250.080.030.31
Yield & Distribution Ratios
Earnings Yield-0.14%-0.05%-0.09%-0.05%0.01%
FCF Yield-0.12%-0.13%-0.07%-0.04%0.04%
Buyback Yield-0.20%-0.09%-0.03%-0.08%-0.18%